[
    [
        {
            "time": "",
            "original_text": "贝达药业：埃克替尼INCREASE研究成 果在《临床肿瘤研究》发表",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "INCREASE研究",
                    "临床肿瘤研究"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：埃克替尼INCREASE研究成 果在《临床肿瘤研究》发表",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：公司控股子公司涉诉案件目前处于待审状态 关联方问题",
            "features": {
                "keywords": [
                    "贝达药业",
                    "控股子公司",
                    "涉诉案件",
                    "待审状态",
                    "关联方问题"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：公司控股子公司涉诉案件目前处于待审状态 关联方问题",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)子公司Xcovery被BETA起诉 涉及服务商标权侵犯纠纷 诉讼纠纷",
            "features": {
                "keywords": [
                    "贝达药业",
                    "Xcovery",
                    "BETA",
                    "起诉",
                    "服务商标权侵犯",
                    "诉讼纠纷"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)子公司Xcovery被BETA起诉 涉及服务商标权侵犯纠纷 诉讼纠纷",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]